Pro-Dex, Inc.
Pro-Dex, Inc. (PDEX) Stock Competitors & Peer Comparison
See (PDEX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PDEX | $59.10 | -0.29% | 188.9M | 16.30 | $3.63 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.47% |
| BDX | $146.35 | +2.01% | 51.6B | 24.88 | $5.72 | +2.47% |
| ALC | $66.92 | +5.15% | 32.1B | 39.49 | $1.67 | +0.54% |
| MDLN | $37.29 | +3.04% | 30.5B | 31.60 | $1.14 | N/A |
| WST | $305.94 | +1.01% | 21.5B | 40.71 | $7.48 | +0.29% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.47% |
| COO | $61.66 | +3.45% | 11.9B | 30.32 | $2.01 | N/A |
| BAX | $18.10 | +4.62% | 9.2B | -9.32 | -$1.91 | +2.03% |
Stock Comparison
PDEX vs BDXA Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, PDEX is priced at $59.10, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas BDXA's P/E ratio is 21.44. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, PDEX is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check BDXA's competition here
PDEX vs BDX Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, BDX has a market cap of 51.6B. Regarding current trading prices, PDEX is priced at $59.10, while BDX trades at $146.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas BDX's P/E ratio is 24.88. In terms of profitability, PDEX's ROE is +0.29%, compared to BDX's ROE of +0.05%. Regarding short-term risk, PDEX is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check BDX's competition here
PDEX vs ALC Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ALC has a market cap of 32.1B. Regarding current trading prices, PDEX is priced at $59.10, while ALC trades at $66.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ALC's P/E ratio is 39.49. In terms of profitability, PDEX's ROE is +0.29%, compared to ALC's ROE of +0.04%. Regarding short-term risk, PDEX is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check ALC's competition here
PDEX vs MDLN Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, MDLN has a market cap of 30.5B. Regarding current trading prices, PDEX is priced at $59.10, while MDLN trades at $37.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas MDLN's P/E ratio is 31.60. In terms of profitability, PDEX's ROE is +0.29%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, PDEX is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check MDLN's competition here
PDEX vs WST Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, WST has a market cap of 21.5B. Regarding current trading prices, PDEX is priced at $59.10, while WST trades at $305.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas WST's P/E ratio is 40.71. In terms of profitability, PDEX's ROE is +0.29%, compared to WST's ROE of +0.18%. Regarding short-term risk, PDEX is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check WST's competition here
PDEX vs HOLX Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, PDEX is priced at $59.10, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas HOLX's P/E ratio is 31.54. In terms of profitability, PDEX's ROE is +0.29%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, PDEX is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check HOLX's competition here
PDEX vs BDXB Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, PDEX is priced at $59.10, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas BDXB's P/E ratio is 7.60. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, PDEX is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check BDXB's competition here
PDEX vs COO Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, COO has a market cap of 11.9B. Regarding current trading prices, PDEX is priced at $59.10, while COO trades at $61.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas COO's P/E ratio is 30.32. In terms of profitability, PDEX's ROE is +0.29%, compared to COO's ROE of +0.05%. Regarding short-term risk, PDEX is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check COO's competition here
PDEX vs BAX Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, BAX has a market cap of 9.2B. Regarding current trading prices, PDEX is priced at $59.10, while BAX trades at $18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas BAX's P/E ratio is -9.32. In terms of profitability, PDEX's ROE is +0.29%, compared to BAX's ROE of -0.16%. Regarding short-term risk, PDEX is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check BAX's competition here
PDEX vs ATR Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ATR has a market cap of 7.4B. Regarding current trading prices, PDEX is priced at $59.10, while ATR trades at $113.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ATR's P/E ratio is 19.82. In terms of profitability, PDEX's ROE is +0.29%, compared to ATR's ROE of +0.14%. Regarding short-term risk, PDEX is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check ATR's competition here
PDEX vs RGEN Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, RGEN has a market cap of 5.9B. Regarding current trading prices, PDEX is priced at $59.10, while RGEN trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas RGEN's P/E ratio is 114.51. In terms of profitability, PDEX's ROE is +0.29%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, PDEX is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check RGEN's competition here
PDEX vs TFX Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, PDEX is priced at $59.10, while TFX trades at $131.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas TFX's P/E ratio is 2175.33. In terms of profitability, PDEX's ROE is +0.29%, compared to TFX's ROE of -0.28%. Regarding short-term risk, PDEX is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check TFX's competition here
PDEX vs BLCO Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, BLCO has a market cap of 5.7B. Regarding current trading prices, PDEX is priced at $59.10, while BLCO trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas BLCO's P/E ratio is -25.98. In terms of profitability, PDEX's ROE is +0.29%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, PDEX is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check BLCO's competition here
PDEX vs AVTR Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, AVTR has a market cap of 5.2B. Regarding current trading prices, PDEX is priced at $59.10, while AVTR trades at $7.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas AVTR's P/E ratio is -9.39. In terms of profitability, PDEX's ROE is +0.29%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, PDEX is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check AVTR's competition here
PDEX vs STVN Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, STVN has a market cap of 4.9B. Regarding current trading prices, PDEX is priced at $59.10, while STVN trades at $17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas STVN's P/E ratio is 29.62. In terms of profitability, PDEX's ROE is +0.29%, compared to STVN's ROE of +0.10%. Regarding short-term risk, PDEX is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check STVN's competition here
PDEX vs MMSI Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, MMSI has a market cap of 3.8B. Regarding current trading prices, PDEX is priced at $59.10, while MMSI trades at $63.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas MMSI's P/E ratio is 27.43. In terms of profitability, PDEX's ROE is +0.29%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, PDEX is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check MMSI's competition here
PDEX vs WRBY Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, WRBY has a market cap of 3.5B. Regarding current trading prices, PDEX is priced at $59.10, while WRBY trades at $27.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas WRBY's P/E ratio is 2862.00. In terms of profitability, PDEX's ROE is +0.29%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, PDEX is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check WRBY's competition here
PDEX vs ICUI Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, PDEX is priced at $59.10, while ICUI trades at $124.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ICUI's P/E ratio is 66.17. In terms of profitability, PDEX's ROE is +0.29%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, PDEX is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check ICUI's competition here
PDEX vs HAE Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, HAE has a market cap of 2.7B. Regarding current trading prices, PDEX is priced at $59.10, while HAE trades at $57.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas HAE's P/E ratio is 15.79. In terms of profitability, PDEX's ROE is +0.29%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PDEX is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check HAE's competition here
PDEX vs LMAT Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, LMAT has a market cap of 2.3B. Regarding current trading prices, PDEX is priced at $59.10, while LMAT trades at $101.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas LMAT's P/E ratio is 37.07. In terms of profitability, PDEX's ROE is +0.29%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, PDEX is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check LMAT's competition here
PDEX vs NVCR Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, PDEX is priced at $59.10, while NVCR trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas NVCR's P/E ratio is -11.41. In terms of profitability, PDEX's ROE is +0.29%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, PDEX is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check NVCR's competition here
PDEX vs XRAY Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, PDEX is priced at $59.10, while XRAY trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas XRAY's P/E ratio is -3.12. In terms of profitability, PDEX's ROE is +0.29%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, PDEX is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check XRAY's competition here
PDEX vs PLSE Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, PLSE has a market cap of 1.8B. Regarding current trading prices, PDEX is priced at $59.10, while PLSE trades at $25.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas PLSE's P/E ratio is -23.28. In terms of profitability, PDEX's ROE is +0.29%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, PDEX is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check PLSE's competition here
PDEX vs STAA Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, STAA has a market cap of 1.6B. Regarding current trading prices, PDEX is priced at $59.10, while STAA trades at $31.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas STAA's P/E ratio is -76.93. In terms of profitability, PDEX's ROE is +0.29%, compared to STAA's ROE of -0.06%. Regarding short-term risk, PDEX is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check STAA's competition here
PDEX vs ATRC Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, PDEX is priced at $59.10, while ATRC trades at $28.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ATRC's P/E ratio is -284.80. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, PDEX is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check ATRC's competition here
PDEX vs NNNN Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, NNNN has a market cap of 1.2B. Regarding current trading prices, PDEX is priced at $59.10, while NNNN trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas NNNN's P/E ratio is 187.67. In terms of profitability, PDEX's ROE is +0.29%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, PDEX is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check NNNN's competition here
PDEX vs KMTS Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, PDEX is priced at $59.10, while KMTS trades at $19.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas KMTS's P/E ratio is -3.59. In terms of profitability, PDEX's ROE is +0.29%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, PDEX is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check KMTS's competition here
PDEX vs BLFS Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, PDEX is priced at $59.10, while BLFS trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas BLFS's P/E ratio is -92.92. In terms of profitability, PDEX's ROE is +0.29%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, PDEX is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check BLFS's competition here
PDEX vs ATRI Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, PDEX is priced at $59.10, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ATRI's P/E ratio is 64.50. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, PDEX is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check ATRI's competition here
PDEX vs AZTA Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, AZTA has a market cap of 748.5M. Regarding current trading prices, PDEX is priced at $59.10, while AZTA trades at $16.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas AZTA's P/E ratio is -6.74. In terms of profitability, PDEX's ROE is +0.29%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, PDEX is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check AZTA's competition here
PDEX vs QDEL Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, QDEL has a market cap of 739.2M. Regarding current trading prices, PDEX is priced at $59.10, while QDEL trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas QDEL's P/E ratio is -0.61. In terms of profitability, PDEX's ROE is +0.29%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, PDEX is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check QDEL's competition here
PDEX vs ANGO Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ANGO has a market cap of 457.4M. Regarding current trading prices, PDEX is priced at $59.10, while ANGO trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ANGO's P/E ratio is -14.57. In terms of profitability, PDEX's ROE is +0.29%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, PDEX is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check ANGO's competition here
PDEX vs OSUR Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, OSUR has a market cap of 207.2M. Regarding current trading prices, PDEX is priced at $59.10, while OSUR trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas OSUR's P/E ratio is -2.87. In terms of profitability, PDEX's ROE is +0.29%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, PDEX is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check OSUR's competition here
PDEX vs UTMD Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, UTMD has a market cap of 203.8M. Regarding current trading prices, PDEX is priced at $59.10, while UTMD trades at $63.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas UTMD's P/E ratio is 18.93. In terms of profitability, PDEX's ROE is +0.29%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, PDEX is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check UTMD's competition here
PDEX vs SMTI Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, SMTI has a market cap of 200.6M. Regarding current trading prices, PDEX is priced at $59.10, while SMTI trades at $21.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas SMTI's P/E ratio is 364.83. In terms of profitability, PDEX's ROE is +0.29%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, PDEX is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check SMTI's competition here
PDEX vs INFU Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, INFU has a market cap of 180.1M. Regarding current trading prices, PDEX is priced at $59.10, while INFU trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas INFU's P/E ratio is 24.12. In terms of profitability, PDEX's ROE is +0.29%, compared to INFU's ROE of +0.14%. Regarding short-term risk, PDEX is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check INFU's competition here
PDEX vs KRMD Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, PDEX is priced at $59.10, while KRMD trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas KRMD's P/E ratio is -76.60. In terms of profitability, PDEX's ROE is +0.29%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, PDEX is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check KRMD's competition here
PDEX vs STXS Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, STXS has a market cap of 174.5M. Regarding current trading prices, PDEX is priced at $59.10, while STXS trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas STXS's P/E ratio is -7.44. In terms of profitability, PDEX's ROE is +0.29%, compared to STXS's ROE of -1.53%. Regarding short-term risk, PDEX is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check STXS's competition here
PDEX vs NYXH Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, NYXH has a market cap of 109.4M. Regarding current trading prices, PDEX is priced at $59.10, while NYXH trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas NYXH's P/E ratio is -1.17. In terms of profitability, PDEX's ROE is +0.29%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, PDEX is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check NYXH's competition here
PDEX vs MBOT Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, MBOT has a market cap of 81.1M. Regarding current trading prices, PDEX is priced at $59.10, while MBOT trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas MBOT's P/E ratio is -6.85. In terms of profitability, PDEX's ROE is +0.29%, compared to MBOT's ROE of -0.15%. Regarding short-term risk, PDEX is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check MBOT's competition here
PDEX vs ZTEK Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ZTEK has a market cap of 79.6M. Regarding current trading prices, PDEX is priced at $59.10, while ZTEK trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ZTEK's P/E ratio is -12.33. In terms of profitability, PDEX's ROE is +0.29%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, PDEX is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check ZTEK's competition here
PDEX vs AKYA Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, PDEX is priced at $59.10, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas AKYA's P/E ratio is -1.34. In terms of profitability, PDEX's ROE is +0.29%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, PDEX is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check AKYA's competition here
PDEX vs DXR Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, DXR has a market cap of 54.5M. Regarding current trading prices, PDEX is priced at $59.10, while DXR trades at $10.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas DXR's P/E ratio is 6.59. In terms of profitability, PDEX's ROE is +0.29%, compared to DXR's ROE of +0.22%. Regarding short-term risk, PDEX is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check DXR's competition here
PDEX vs OMIC Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, PDEX is priced at $59.10, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas OMIC's P/E ratio is -0.58. In terms of profitability, PDEX's ROE is +0.29%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, PDEX is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check OMIC's competition here
PDEX vs IGAP Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, PDEX is priced at $59.10, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas IGAP's P/E ratio is -10.52. In terms of profitability, PDEX's ROE is +0.29%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, PDEX is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check IGAP's competition here
PDEX vs STSS Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, STSS has a market cap of 45.9M. Regarding current trading prices, PDEX is priced at $59.10, while STSS trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas STSS's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to STSS's ROE of -1.66%. Regarding short-term risk, PDEX is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check STSS's competition here
PDEX vs NEPH Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, NEPH has a market cap of 40M. Regarding current trading prices, PDEX is priced at $59.10, while NEPH trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas NEPH's P/E ratio is 52.57. In terms of profitability, PDEX's ROE is +0.29%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, PDEX is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check NEPH's competition here
PDEX vs POCI Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, POCI has a market cap of 39.3M. Regarding current trading prices, PDEX is priced at $59.10, while POCI trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas POCI's P/E ratio is -7.94. In terms of profitability, PDEX's ROE is +0.29%, compared to POCI's ROE of -0.37%. Regarding short-term risk, PDEX is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check POCI's competition here
PDEX vs SDC Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, PDEX is priced at $59.10, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas SDC's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to SDC's ROE of -1.96%. Regarding short-term risk, PDEX is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check SDC's competition here
PDEX vs MLSS Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, MLSS has a market cap of 28.7M. Regarding current trading prices, PDEX is priced at $59.10, while MLSS trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas MLSS's P/E ratio is -5.43. In terms of profitability, PDEX's ROE is +0.29%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, PDEX is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check MLSS's competition here
PDEX vs EKSO Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, PDEX is priced at $59.10, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas EKSO's P/E ratio is -2.31. In terms of profitability, PDEX's ROE is +0.29%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, PDEX is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check EKSO's competition here
PDEX vs IVC Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, PDEX is priced at $59.10, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas IVC's P/E ratio is -0.79. In terms of profitability, PDEX's ROE is +0.29%, compared to IVC's ROE of -0.46%. Regarding short-term risk, PDEX is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check IVC's competition here
PDEX vs HBIO Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, HBIO has a market cap of 22.6M. Regarding current trading prices, PDEX is priced at $59.10, while HBIO trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas HBIO's P/E ratio is -2.33. In terms of profitability, PDEX's ROE is +0.29%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, PDEX is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check HBIO's competition here
PDEX vs RVP Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, PDEX is priced at $59.10, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas RVP's P/E ratio is -1.59. In terms of profitability, PDEX's ROE is +0.29%, compared to RVP's ROE of -0.08%. Regarding short-term risk, PDEX is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check RVP's competition here
PDEX vs ZJYL Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ZJYL has a market cap of 19.1M. Regarding current trading prices, PDEX is priced at $59.10, while ZJYL trades at $2.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ZJYL's P/E ratio is 12.20. In terms of profitability, PDEX's ROE is +0.29%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, PDEX is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check ZJYL's competition here
PDEX vs FEMY Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, FEMY has a market cap of 10.7M. Regarding current trading prices, PDEX is priced at $59.10, while FEMY trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas FEMY's P/E ratio is -1.51. In terms of profitability, PDEX's ROE is +0.29%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, PDEX is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check FEMY's competition here
PDEX vs RGNT Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, RGNT has a market cap of 7.6M. Regarding current trading prices, PDEX is priced at $59.10, while RGNT trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas RGNT's P/E ratio is -0.08. In terms of profitability, PDEX's ROE is +0.29%, compared to RGNT's ROE of N/A. Regarding short-term risk, PDEX is more volatile compared to RGNT. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check RGNT's competition here
PDEX vs NSTG Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, PDEX is priced at $59.10, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas NSTG's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, PDEX is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check NSTG's competition here
PDEX vs NXGL Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, NXGL has a market cap of 4.7M. Regarding current trading prices, PDEX is priced at $59.10, while NXGL trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas NXGL's P/E ratio is -1.28. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, PDEX is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check NXGL's competition here
PDEX vs NXGLW Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, NXGLW has a market cap of 4.3M. Regarding current trading prices, PDEX is priced at $59.10, while NXGLW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas NXGLW's P/E ratio is -0.04. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, PDEX is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check NXGLW's competition here
PDEX vs LUCY Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, LUCY has a market cap of 3.8M. Regarding current trading prices, PDEX is priced at $59.10, while LUCY trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas LUCY's P/E ratio is -0.49. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, PDEX is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check LUCY's competition here
PDEX vs POAI Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, PDEX is priced at $59.10, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas POAI's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to POAI's ROE of -107.05%. Regarding short-term risk, PDEX is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check POAI's competition here
PDEX vs MHUA Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, PDEX is priced at $59.10, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas MHUA's P/E ratio is 0.25. In terms of profitability, PDEX's ROE is +0.29%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, PDEX is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check MHUA's competition here
PDEX vs GMVD Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, PDEX is priced at $59.10, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas GMVD's P/E ratio is -0.01. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check GMVD's competition here
PDEX vs GMVDW Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, PDEX is priced at $59.10, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas GMVDW's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check GMVDW's competition here
PDEX vs AVGR Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, PDEX is priced at $59.10, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas AVGR's P/E ratio is -0.05. In terms of profitability, PDEX's ROE is +0.29%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, PDEX is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check AVGR's competition here
PDEX vs STSSW Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, STSSW has a market cap of 867.5K. Regarding current trading prices, PDEX is priced at $59.10, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas STSSW's P/E ratio is -0.04. In terms of profitability, PDEX's ROE is +0.29%, compared to STSSW's ROE of -1.66%. Regarding short-term risk, PDEX is more volatile compared to STSSW. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check STSSW's competition here
PDEX vs LUCYW Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, PDEX is priced at $59.10, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas LUCYW's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, PDEX is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check LUCYW's competition here
PDEX vs GCTK Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, GCTK has a market cap of 274.1K. Regarding current trading prices, PDEX is priced at $59.10, while GCTK trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas GCTK's P/E ratio is -0.02. In terms of profitability, PDEX's ROE is +0.29%, compared to GCTK's ROE of -2.83%. Regarding short-term risk, PDEX is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check GCTK's competition here
PDEX vs WOK Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, WOK has a market cap of 2.2K. Regarding current trading prices, PDEX is priced at $59.10, while WOK trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas WOK's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to WOK's ROE of -0.07%. Regarding short-term risk, PDEX is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.Check WOK's competition here
PDEX vs ARTC Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ARTC has a market cap of 0. Regarding current trading prices, PDEX is priced at $59.10, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ARTC's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to ARTC's ROE of N/A. Regarding short-term risk, PDEX is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check ARTC's competition here
PDEX vs APR Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, APR has a market cap of 0. Regarding current trading prices, PDEX is priced at $59.10, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas APR's P/E ratio is 22.59. In terms of profitability, PDEX's ROE is +0.29%, compared to APR's ROE of +9.81%. Regarding short-term risk, PDEX is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check APR's competition here
PDEX vs ATRS Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, PDEX is priced at $59.10, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ATRS's P/E ratio is 14.95. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, PDEX is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check ATRS's competition here
PDEX vs IVTY Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, PDEX is priced at $59.10, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas IVTY's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, PDEX is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check IVTY's competition here
PDEX vs HRC Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, HRC has a market cap of 0. Regarding current trading prices, PDEX is priced at $59.10, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas HRC's P/E ratio is 41.92. In terms of profitability, PDEX's ROE is +0.29%, compared to HRC's ROE of +0.14%. Regarding short-term risk, PDEX is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check HRC's competition here
PDEX vs ALOG Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, PDEX is priced at $59.10, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas ALOG's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, PDEX is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check ALOG's competition here
PDEX vs IIN Comparison May 2026
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 188.9M. In comparison, IIN has a market cap of 0. Regarding current trading prices, PDEX is priced at $59.10, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 16.30, whereas IIN's P/E ratio is 226.45. In terms of profitability, PDEX's ROE is +0.29%, compared to IIN's ROE of -0.00%. Regarding short-term risk, PDEX is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.Check IIN's competition here